Skip to main content
Aclaris Therapeutics, Inc.SEC 8-K

Aclaris Initiates Phase 2b ALPHA Trial of Modzatinib in Moderate-to-Severe Lichen Planus

What happened

On November 16, 2026, Aclaris announced the initiation of its randomized, double-blind, placebo-controlled Phase 2b ALPHA trial evaluating modzatinib (ATI-2138) in patients with moderate-to-severe lichen planus, with top line results from the oral erosive...

Source

Extracted by Autobound

From the Signal API record
Signal
SEC 8-K

What this signalsFilings often name leadership changes, deals and spending plans.

Filed
Nov 16, 2026

More SEC 8-K signals at other companies

The full record

From the Signal API record

Details

CIK
1557746
Accession number
0001104659-26-127478
Timeframe
Next year
Filing year
2026
Why it matters
Clinical and commercial build-out
Signal category
Strategic

Topics and mentions

Regions named

  • U.S.

Extraction

Confidence
High
Relevance
85%
Sentiment
Positive
Detected
Nov 17, 2026
signal_type
sec-8k
signal_subtype
clinicalMilestone

Use this data

Get every SEC 8-K signal for Aclaris Therapeutics, Inc. and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Aclaris Therapeutics, Inc. this week?”

  2. Send it to your own tools

    The Signal API returns SEC 8-K signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-8k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/e2de7f75-7635-4555-a546-514930392d91 returns this record as JSON. POST /v1/companies/enrich returns every signal for aclaristx.com.

{
  "signal_id": "e2de7f75-7635-4555-a546-514930392d91",
  "signal_type": "sec-8k",
  "signal_subtype": "clinicalMilestone",
  "detected_at": "2026-11-17T07:03:12.712+00:00",
  "company": {
    "name": "Aclaris Therapeutics, Inc.",
    "domain": "aclaristx.com"
  },
  "data": {
    "detail": "On November 16, 2026, Aclaris announced the initiation of its randomized, double-blind, placebo-controlled Phase 2b ALPHA trial evaluating modzatinib (ATI-2138) in patients with moderate-to-severe lichen planus, with top line results from the oral erosive lichen planus cohort expected in the second half of 2027. For sellers: Clinical research organizations, trial recruitment vendors, and specialty CROs may see demand for ongoing trial execution and future phase preparation.",
    "metrics": {
      "timeframe": "next_year"
    },
    "summary": "Aclaris Initiates Phase 2b ALPHA Trial of Modzatinib in Moderate-to-Severe Lichen Planus",
    "relevance": 0.85,
    "sentiment": "positive",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/1557746/000110465926127478/acrs-20261116x8k.htm",
    "filing_date": "2026-11-16",
    "filing_year": 2026,
    "sales_relevance": "Clinical and commercial build-out",
    "signal_category": "strategic",
    "regions_mentioned": [
      "U.S."
    ]
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.